No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
No Data
Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report
Cassava Sciences Shares Plunge on Indictment Against Former Advisor -- Barrons.com
Needham Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $294
Express News | Needham Reiterates Buy on Biogen, Maintains $294 Price Target
Biogen, Eisai Launch Leqembi in China to Treat Alzheimer's Disease
Eisai and Biogen Launch Alzheimer's Drug Leqembi in China